Authors’ reply to Schaffalitzky de Muckadell and colleague’s Comment on “Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017”

Birgit Ehlken, Lennart Nathell, Annegret Gohlke (), Derya Bocuk, Massoud Toussi and Stefan Wohlfeil
Additional contact information
Birgit Ehlken: IQVIA
Lennart Nathell: Nathell Medical AB
Annegret Gohlke: IQVIA
Derya Bocuk: IQVIA
Massoud Toussi: IQVIA
Stefan Wohlfeil: Vifor Pharma Management Ltd.

Drug Safety, 2019, vol. 42, issue 5, No 12, 693-696

Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-019-00815-4 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:42:y:2019:i:5:d:10.1007_s40264-019-00815-4

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-019-00815-4

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().